Oncoustics

On a global scale, liver disease has become one of the fastest-growing causes of death with two billion of the world’s population currently at risk. Oncoustics is creating a surveillance and diagnostics tool that detects liver disease early and is easier, faster and less invasive than traditional methods. 

Oncoustics’ first product, the OnX Liver Assessment Solution, uses machine learning and AI to measure the sound in an ultrasound, allowing the scan to deliver more information than what is seen with the human eye. While the technology can differentiate between healthy and diseased tissues anywhere in the body, the company is currently focusing on liver disease because it is an area of huge unmet clinical need and is both complicated and expensive to diagnose. The Oncoustics approach is painless and doesn’t require an expert radiologist to do the scan.

Oncoustics has close ties with the University of Calgary. With UCeed investment, the startup is conducting a clinical research study with Dr. Stephen Congly, an expert in advanced liver disease within the Cumming School of Medicine (CSM). Another UCalgary expert, Dr. Samual Lee, professor and hepatologist at CSM, is the company’s chief medical advisor. The company is leveraging this expertise as it continues to commercialize its technology and work toward FDA submission and approval. 

Visit Oncoustics’ website for more information.

Oncoustics has received investment from UCeed, a venture philanthropy fund accelerating UCalgary and community-based startup companies to advance problem-solving research, create jobs and fuel the economy. A key program in the UCalgary innovation ecosystem, UCeed bridges the gap between innovation, demonstration and commercialization, and is managed by UCalgary’s knowledge-transfer and business incubator, Innovate Calgary.

UCeed Health Fund is supported by the generosity of the River Fund at the Calgary Foundation and its mission to build a healthy and vibrant community where everyone belongs.